IRICoR and the Quebec Breast Cancer Foundation: Joint $3M investment for new treatments
The pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer. In this context, IRICoR and the Quebec Breast Cancer Foundation (QBCF) have joined forces to fund research on breast cancer, a cancer that affects a large and vulnerable population. Today, they proudly announce the four recipients of their joint LeadAction|Breast Cancer du Sein Competition, launched across Canada. These winning investigators from Quebec will benefit from a total amount of 3 million dollars over three years, with $1.5M coming from IRICoR and $1.5M from the QBCF.
This substantial support will enable recipients to accelerate their innovative breast cancer research work in order to offer more therapeutic options to those affected. The projects selected target two major breast cancer issues:
Understanding why certain types of breast cancer are treatment-resistant and thus fight these resistance mechanisms with new therapies.
Developing new treatments for aggressive types of breast cancer, such as triple-negative and HER2-dependent.